Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study.

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Abstract Text:

Shahnaz Shahinfar,Tania Z Dickson,Tultul Ahmed,Zhonxin Zhang,Denise Ramjit,Ronald D Smith,Barry M Brenner, ,

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. BACKGROUND: Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria. Additional questions concerning the reduction of proteinuria and its relationship to end-stage renal disease (ESRD) as well as cardio-renal outcomes and the safety and tolerability of losartan remain to be addressed. METHODS: Three analyses were performed: (a) the impact of losartan on the relationship between the reduction of proteinuria and ESRD; (b) a time-to-event analysis of the cardio-renal composite endpoint of ESRD, myocardial infarction, stroke or all-cause death; and (c) additional analyses of adverse events, particularly in patients with serum creatinine >/=2.0 mg/dL. RESULTS: After adjusting the values for proteinuria over the entire study, the reduction of proteinuria accounted for approximately half of the treatment effect of losartan on the risk reduction for ESRD. In addition, losartan was associated with a 21% risk reduction for the composite cardio-renal outcome (P = 0.003). The addition of losartan to a conventional antihypertensive regimen did not increase the overall incidence of adverse events, regardless of severity of renal impairment. CONCLUSIONS: Losartan significantly reduced the risk of cardiorenal outcomes and was well tolerated by patients, including those with serum creatinine levels >/=2.0 g/dL. In addition, although this study shows that the reduction of proteinuria does not completely explain the impact of intervention on outcomes such as ESRD, reduction of proteinuria must remain an important consideration when treating patients with type 2 diabetes and nephropathy. However, the reduction of outcomes such as ESRD should remain the goal of therapy when evaluating renal protection in this patient population.

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Publishing Authors By Initials

S Shahinfar,TZ Dickson,T Ahmed,Z Zhang,D Ramjit,RD Smith,BM Brenner, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Kidney international. Supplement

VOLUME:

Page Numbers: 64-7

Journal Abbreviation: Kidney Int. Suppl.

ISSN: 0098-6577

DAY: 4

MONTH: Dec

YEAR: 2002

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7508622

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Kidney Int Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study Related Publications

• Adolescents as victims of familial violence: a hospital based surveillance.
• An S6 mutation in BK channels reveals beta1 subunit effects on intrinsic and voltage-dependent gating.
• Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception.
• BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells.
• Cadherin-11 in synovial lining formation and pathology in arthritis.
• Cost-saving analysis of screening colonoscopy in Germany.
• Differential role of I kappa B kinase 1 and 2 in primary rat hepatocytes.
• Effect of insulin on the oxidative desaturation ofa-linolenic, oleic and palmitic acids.
• Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany.
• Fifth Annual ISHAGE Meeting - Oslo 1999.
• Haptic search with finger movements: using more fingers does not necessarily reduce search times.
• Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study.
• Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+.
• Non-invasive in vivo diffuse optical spectroscopy monitoring of cyanide poisoning in a rabbit model.
• Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.
• Protein molecular function prediction by Bayesian phylogenomics.
• Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks.
• Relation between neural response telemetry thresholds, T- and C-levels, and loudness judgments in 12 adult nucleus 24 cochlear implant recipients.
• Relative incorporation of linoleic and arachidonic acid in phospholipids and triglycerides of different rat tissues.
• Symptoms of anxiety and depression in patients with stable coronary heart disease: prognostic value and consideration of pathogenetic links.
• Systemic mediators induce fibrogenic effects in normal liver after partial bile duct ligation.
• Testing the stand-alone microbeam at Columbia University.
• The continuing contribution of gene marking to cell and gene therapy.
• The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells.
• The more eyes, the better to see? From double to quadruple reading of screening mammograms.
• The phosphatidyl ethanolamine ofPseudomonas aeruginosa grown in hexadecane.
• Timely disclosure of progress in childhood cancer survival by 'period' analysis in the Automated Childhood Cancer Information System.
• Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?
• Update on the pfam5000 strategy for selection of structural genomics targets.
• Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts.